Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
VIALE-M trial: what clinicians have said so far
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
- NCT04102020 ↗
- Completed
- AbbVie
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on VIALE-M yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on VIALE-M so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Venetoclax; Azacitidine; Azacitidine
- Arms
- Part 1: Dose Confirmation · Experimental
- Part 3 (Dose Finding): Dose Escalation · Experimental
- Part 3 (Dose Finding): Safety Expansion · Experimental
- Enrollment
- 112
- Primary outcomes
- Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1)
- Number of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion)
- Sponsor
- AbbVie with Roche-Genentech
- Start
- Mar 26, 2020
- Primary completion
- Sep 29, 2022
- Results posted
- Yes
- Registry record
- NCT04102020 · updated Apr 8, 2026
Publications
linked from the registry- Ivanov V, Yeh SP, Mayer J, Saini L, Unal A, Boyiadzis M, Hoffman DM, Kang K, Addo SN, Mendes WL, Fathi AT. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncol. 2022 Aug;18(26):2879-2889. doi: 10.2217/fon-2022-0450. Epub 2022 Jul 19. PubMed 35852098
- Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol. 2021 Mar 1;28(2):110-121. doi: 10.1097/MOH.0000000000000637. PubMed 33394722